A Strategic Partnership to Transform Hearing Treatment

Under this partnership, RHI and Myrtelle will work together to achieve breakthroughs in multiple areas, including:

• Refined gene-editing techniques for hereditary hearing loss conditions.
• Optimized delivery systems to target specific cells within the inner ear.
• Extensive preclinical research to validate treatment efficacy and safety.

This collaborative approach combines RHI’s auditory expertise with Myrtelle’s advanced gene therapy platforms, creating a powerful synergy to address genetic hearing disorders.

Pathway to Clinical Applications

The partnership will initially focus on preclinical studies, establishing a strong foundation of evidence that will pave the way for future clinical trials. This methodical approach emphasizes both scientific rigor and a commitment to bringing effective treatments to patients as quickly as safely possible.

“This partnership is a significant step forward in our mission to eliminate hearing loss as a chronic condition,” said Jim Ayala, CEO of Rescue Hearing Inc. “By combining our expertise with Myrtelle’s cutting-edge technology, we are poised to make real progress in restoring hearing for millions worldwide.”

Addressing a Global Health Challenge

With hearing loss affecting hundreds of millions of individuals globally, this collaboration represents a critical advancement toward offering life-changing treatments for those affected by genetic hearing impairments. Both companies share a vision of transforming auditory healthcare through innovative therapeutic approaches.

Contact Information